Skip to content
Screener

Kailera Therapeutics KLRA Net Change in Cash

Net Change in Cash at other companies

BK
BKBK
$1.53B-46.1%
Veradermics logo
VeradermicsMANE
$146.65M+810%
GPA
General Purpose Acquisition Corp.GPAC
-$2.24M-432%
Polaryx Therapeutics, Inc. logo
Polaryx Therapeutics, Inc.PLYX
13,050,000%-102,425,000pp
Schering-Plough logo
Schering-PloughSGP
$142.54M+242%
Dycom Industries logo
Dycom IndustriesDY
-$170.34M-122%

Other financials

Income statement

See full
Operating income-$84.7M-314%
Net income-$78.9M-339%
EPS (diluted)-$3,650.00+79.7%

Balance sheet

See full
Cash & equivalents$111.8M+9.9%
Total debt$10.5M—
Total equity-$432.1M-83.7%
Total assets$624.8M—

Cash flow

See full
Operating cash flow-$68.3M-275%

Valuation

See full
Market cap$2.44B-15.8%
Enterprise value$2.34B—

Returns & leverage

See full
Debt / equity-0×—
Current ratio9.7×—

Where this comes from

Reported directly by Kailera Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect.

The source filing: Kailera Therapeutics’s 10-Q, filed May 26, 2026. Open the filing →

Filed
May 26, 2026, 4:29 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-239417

FAQ

What is Kailera Therapeutics's net change in cash?
Kailera Therapeutics (KLRA) reported net change in cash of -$48.44M in Q1 2026.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.

Ask your AI about Kailera Therapeutics's net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude